ArticleInvestigational new drugs2018

Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors.

Tomohiro Nishina et al.PubMed ↗Publisher ↗

No numbers read from the abstract.